Latest Earnings Results: Q3 '26
Estimated EPS
-$0.89
Reported EPS
-$0.99
Surprise
-10.84%
Estimated Rev
$4.2M
Reported Rev
$3.38M
Surprise
-19.44%
• Reported GAAP EPS of -$0.99 down -67.80% YoY • Reported revenue of $3.38M down -72.96% YoY • LENZ Therapeutics expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70M to $75M, excluding stock-based compensation.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.75 | -- | -- | N/A |
Q3 '26 | -$0.89 | -$0.99 | -10.84% | MISSED |
Q2 '26 | -$1.05 | -$1.02 | 2.90% | BEAT |
Q1 '26 | -$1.05 | -$1.32 | -25.99% | MISSED |
Q4 '25 | -$0.91 | -$1.16 | -27.71% | MISSED |